Atea Pharmaceuticals, Inc. (AVIR) stock intrinsic value fair value estimate & owner earnings analysis

Atea Pharmaceuticals is a clinical-stage biotechnology company developing oral antivirals. Its lead program is the combination of bemnifosbuvir and ruzasvir for chronic hepatitis C, now in two Phase 3 trials against the current standard regimen of sofosbuvir and velpatasvir: C-BEYOND (United States and Canada, over 880 patients, results expected mid-2026 per the annual report) and C-FORWARD (outside North America, results expected at year-end 2026). A second candidate, AT-587 for hepatitis E, is earlier stage. The company has no approved product and no product sales. What the business earns today: after adjusting operating cash flow for working-capital swings, stock compensation and capital spending, the company has lost roughly $124 million to $180 million a year on this basis from 2022 through 2025 (about $2.08 per share in 2025). The one positive year, 2021, is not a real profit: it reflects the release of an upfront payment from a Roche license agreement that was collected in 2020, so we exclude it. Earlier years describe a much smaller company. There is no positive earnings level to anchor a valuation. Bear, base and bull cases: we value each case at $0 per share. Under our approach, value has to come from something already in hand, such as sales, a signed contract or a demonstrated record of cash generation. Atea has none of these today. Approval of the hepatitis C regimen would be the key event, but it depends on trial results that have not yet been reported and on a regulatory decision, so we do not credit it in any case, and we do not try to estimate a probability-weighted launch. We also do not add the company's cash to the value. Cash, cash equivalents and marketable securities were $301.8 million at December 31, 2025, and the company says this funds operations through 2027, but that money is being spent on trials at a rate of about $130 million a year in operating cash outflow, so it is a runway, not a source of owner earnings. What could make this wrong: a positive Phase 3 readout and approval could create a real business, since hepatitis C affects a large patient population and Atea is testing an 8-week, once-daily regimen. A milestone of $10 million to Roche is due if a marketing application is accepted, which shows the license terms would take a share of any success. If that happens, the valuation would be revisited using actual sales and cash flows rather than trial expectations. The opposite risk is that a trial misses its goals, or the cash runs low before approval and forces the company to issue new shares at a dilutive price. Accounting notes: 2022 through 2025 operating cash flow was lower than net loss plus stock compensation and working-capital changes by roughly $5 million to $15 million in some years, most likely non-cash income items on investments that we did not separately break out; we used the reported cash flow. Capital spending has been small and is not separately reported for 2023 to 2025; we treated it as zero, which does not change the conclusion. Margin-of-safety price: no positive margin-of-safety price is set today, because we cannot name an evidenced source of earnings. The estimate would be revisited after approval and a period of demonstrated product sales.